Tonghua Dongbao Begins Phase II Trial for GLP-1/GIP Agonist THDBH120 in Weight Loss
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has announced a significant milestone in its clinical development...
Obesity
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development
UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by...
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...
Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage
China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...
CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study
China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management
Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...
Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced that it has received approval from...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...
Eli Lilly’s Zepbound Outperforms Wegovy in SURMOUNT-5 Weight Loss Study
US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has revealed a positive readout from...
Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...
Amgen’s MariTide Showcases Significant Weight Loss in Phase II Study
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase...
Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...
Pfizer and Flagship Pioneering Expand Partnership with Two New Biotechnology Agreements
The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company...
Sihuan Pharmaceutical’s Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced an exclusive licensing agreement between...
Guangdong Zhongsheng Pharmaceutical’s RAY1225 Shows Positive Results in Phase II Study
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced positive top-line...